INTRODUCTION
Year after year, conditions, quality, and duration of human lives have been improving due to the progress of science, technology, education, and medicine, which however has a downside. Owing to improvement in children's nutrition, developmental acceleration occurs that imbalances a child's system. Because of virtual worlds of the Internet, social experience of teenagers expands and clashes with puberty of adolescents. Due to the comfort of cities, urbanization emerges and causes stress to adults because of artificial light, noise, pollution, violations of personal space, and family disruption. At old age, all these factors taken together contribute to loneliness, cancer, diabetes, drug addiction, and sporadic Alzheimer's disease (AD), which shorten the lifespan, as reviewed in the US, 1990-2010 (1). That is why, a person may ask oneself: "What can I do now to keep my health in my old age?" This personal initiative in health maintenance is one of the main reasons behind predictive preventive personalized medicine (2). This newest branch of molecular medicine uses single nucleotide polymorphisms to prevent diseases on the basis of the difference between the individual and reference human genomes.
Before the genomics era, discovery of the associations between SNPs and diseases was mostly due to luck (3, 4). Now, in the postgenomic era, such studies are systematic and genomewide within the framework of the large worldwide project "1000 Genomes" (5). The results of the project are stored in the dbSNP database as true SNPs (6). This database is an inherent part of the reference human genome and contains ancestral alleles of all SNPs, whereas the human variome represents their minor alleles. Currently the database contains over 8.58 billion known unannotated SNPs (7), which can be mapped using the UCSC Genome Browser (8). In turn, biomedical databases GWAS (genomewide association study) (9), OMIM (10), ClinVar (11), and HapMap (12) annotate these SNPs by documenting associations with hereditary diseases and with their complications and comorbidities (e.g., (13) ). Each such association is characterized by the statistical significance of the discrimination between a cohort of patients with a given disease and healthy volunteers (as a control), with the SNPs serving as biomarkers of this disease according to a conventional clinical protocol (14) . The vast majority of SNPs are neutral while only a tiny minority is biomedical SNP markers as was postulated by the theory of neutral evolution (15) and Haldane's dilemma (16) . Therefore, the clinical search for SNP markers of diseases by "trial and error" is very slow, costly, and labor-intensive.
Most of currently known biomedical SNP markers have been found within protein-coding gene regions where their manifestations are invariant and easily detectable because of the disruption in both structure and function of the altered protein (10). Nevertheless, neither medication nor a lifestyle change can fully correct pathological effects of these SNPs; that is why they are rather valuable for physicians but not for people who would like to prevent various diseases by sequencing their individual genome. In contrast, the smallest number of biomedical markers has been found in the regulatory regions of genes, where the mutations alter only the concentration of a protein in human cells without any damage to the structure and function of this protein (17) . Because nothing changed in proteins but their concentrations, the pathological effects of these regulatory biomedical SNP markers should be correctable by medications and/or lifestyle changes. For this reason, such biomedical SNP markers can be interesting both to physicians (may help to improve patient care) and to people who would like to prevent such diseases by sequencing their individual genome.
The majority of the known regulatory biomedical SNP markers alter the binding site for TATA-binding protein (TBP) because they are located within the small region (-70; -20) upstream of the transcription start site (18) . These SNP markers are readily detectable due to the positive correlation between the expression level of the human gene containing them and the affinity of TBP for the promoter of this gene (19) . This is because TBP's binding to its binding site is the very first obligatory molecular event of transcription initiation in eukaryotes (20, 21) . © 1996-2017 For the remaining ~2,600 DNA-binding proteins (22) , experimental data on their binding to human gene promoters in health (23), in disease (24), and after treatment (25) are still being accumulated.
Computer-based elimination of neutral SNPs among the known unannotated SNPs (7) may accelerate and facilitate the clinical search for biomedical SNP markers (4). This task can be performed by means of many publicly available Web services performing well only on some SNPs and diseases ((26-42); for a review, see (43, 44) ). The most advanced software appears to be targeted to the dynamics of molecular structures and allows researchers to estimate the SNP-caused changes in proteins (e.g. (45)). The new trend in this active field of research is Web navigation services that help users to generate their own ideas on how an SNP of interest can affect symptoms of diseases under study by predicting how this SNP can alter the protein's structurefunction relation (46). Another innovation is Web service PredictSNP2 (47). It expresses the numerical estimates of alteration in a protein's structure-function relations caused by an SNP as qualitative categories of human health (47). These categories are more understandable to the general population.
Meanwhile, the smallest progress has been made on regulatory SNPs because their manifestations may vary from cell to cell, from tissue to tissue, from patient to patient, and from subpopulation to subpopulation without any changes in a protein's structure-function relations (48). That is why development of the approaches to computerbased prediction of candidate SNP markers of human hereditary diseases within regulatory gene regions is a challenging problem that limits the progress of predictive preventive personalized medicine (2).
Trying to find an answer to the question "What can be done to keep one's health at old age?" here we provide a comprehensive review on the topic of known and candidate regulatory SNP markers of hereditary diseases. This review is focused on the markers near the TBP-binding sites of human gene promoters because these regulatory sites have been studied the most. For example, one of such candidate SNP markers is rs72661131, which is associated with stroke and sporadic AD (49). Risks of both diseases can be minimized by adding some natural marine products into the diet of an individual who has a minor allele of this SNP (50). Of course, this is oversimplification: if stroke and sporadic AD could be prevented by a natural marine diet alone, the life of the general population would be easy. Nevertheless, this candidate SNP marker may be interesting for people who would like to bring their lifestyle in line with their sequenced individual genome. Thus, we focused this review on a public Web service called SNP_TATA_ Comparator (http://beehive.bionet.nsc.ru/cgi-bin/mgs/ tatascan/start.pl), which was developed specifically for predicting the candidate SNP markers near the TBPbinding sites of human gene promoters (51).
WEB-SERVICE SNP_TATA_COMPARATOR
The Web-service SNP_TATA_Comparator, http://beehive.bionet.nsc.ru/cgi-bin/mgs/tatascan/ start.pl, calculates a computer-based statistical estimation of SNP-caused alteration of TBP's binding affinity for a human gene promoter. Based on this estimate, the Web-service SNP_TATA_Comparator predicts a change in the expression of the genes that can be associated with diseases, their comorbidities, and complications (51). Let's see how to use it and review its bioinformatics model, hardware platform, and software design in more detail.
How to use WEB service SNP_TATA_Comparator
Figure 1 illustrates how a person can use SNP_TATA_Comparator (51) in practice. As a preliminary preparation, he or she should first find the human gene, the promoter of this gene, and the SNPs of this promoter, using another public Web service "UCSC Genome Browser" (8) as shown in Figure 1 A.
Next, using the BioPerl library (52), the user can extract the promoter sequences containing these SNPs from the reference human genome (5) by means of Web service SNP_TATA_Comparator (51) as shown in Figure 1 B. Here, the "Base sequence" textbox contains the ancestral allele of the promoter of interest. Another "Editable sequence" textbox contains a copy of this DNA sequence, where the user should manually create the minor allele of interest according to its description from the dbSNP database (6) available via Web service "UCSC Genome Browser" (8). Clicking on the "Calculate" button transforms these two DNA sequences as the input data into the output data appearing in the "Result" textbox as shown in Figure 1 , B and C. This transformation is based on a bioinformatics model shown in Figure 2 and described in detail in section 3.2. Finally, the line "DECISION" shows the prediction made by SNP_ TATA_Comparator (51) using this model. Additionally, the line "Z-score" shows the p value of the probability rate of this prediction (where: alpha = 1 -p is its statistical significance).
Bioinformatics model
The bioinformatics model of the Web service SNP_TATA_Comparator (51) takes into account three steps of TBP's binding to a eukaryotic gene promoter, namely: (i) TBP slides along DNA (53-55) <=> (ii) TBP stops at a TBP-binding site (56; 57) <=> (iii) the TBPpromoter complex is fixed by DNA helix's bending to
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© 1996-2017 the 90° angle (58-60). This binding affinity can be estimated using the following empirical equation:
(1)
where 10.9 (ln units) is nonspecific TBP-DNA affinity 10 -5 M (61), 0.2 is the stoichiometric coefficient (62), and K STOP is the maximal score-value of Bucher's position-weight matrix, which is the commonly accepted criterion of the TATA box: the canonical form of the TBP-binding site (57).
In Eq. (1), K SLIDE is our empirical estimate of the equilibrium constant of TBP's sliding along DNA (this constant was determined experimentally (53)), namely:
(2) (-70; -20) (where all proven TBP-binding sites (boxed) are located; double-headed arrow) of the human MBL2 gene promoter. These data were retrieved from dbSNP (6) using the UCSC Genome Browser (8). Dash-and-double-dot arrows: known and candidate biomedical SNP markers are predicted by a significant change in the affinity of TBP for the human MBL2 gene promoter. (B, C) The results produced by Web service SNP_TATA_Comparator (51) for the two SNP markers of the hereditary diseases in question: known rs72661131 (77-79) and candidate marker rs567653539 near the known TATA box (boxed) of the human MBL2 gene promoter. Solid, dotted, and dashed arrows indicate queries for the gene list, list of transcripts of a given gene, and DNA sequence of the promoter corresponding to the specified transcript in terms of the BioPerl library (52) of the reference human genome (5), respectively. Dash-and-dot arrows: estimates of significance of the alteration of gene product abundance in patients with the minor allele (mt) relative to the norm (ancestral allele, wt) expressed as a Z-score (the ratio of the difference between two means to the square root of the sum of the squares of their standard errors) using package R (66). Circles indicate the ancestral (wt) and minor (mt) alleles of the SNP marker labeled with its dbSNP ID (6).
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© 1996-2017 where (TA) 3'HALF is the total amount of dinucleotide TA within the 3' half of the DNA sequence being analyzed; MinorGrooveWidth REGION is the mean width of the minor groove of the B-form of the DNA helix (54); 0.8, -3.4, and -35.1 are linear regression coefficients (62); MEAN 15bp is the mean arithmetic value for all possible positions and orientations of the TBPbinding site, 15 bp long (this value was determined empirically (53)).
In Eq.
(1), K BEND is our empirical estimate of the equilibrium constant at the DNA helix bending step on the basis of the macromolecular dynamics computations (58) describing how TBP can bind to DNA, namely:
where WR = {TA, AA, TG, AG}, TV = {TA, TC, TG} (63) (the IUPAC-IUB nomenclature (64)); 0.9, 2.5, and 14.4 are linear regression coefficients taken from ref.
(63); MEAN TATA-box is the mean arithmetic value for both DNA strands of the TBP-binding site at the position of the maximal score-value of Bucher's position-weight matrix (57).
Additionally, the estimates of standard deviation of the -ln(K D ) (Eq. 1)-for 78 possible substitutions, s i+j →X, at each j-th position (-14 < j < 13; 78 = 3 * 26) within the 26-bp DNA window-was heuristically estimated as Then, the Z-value obtained is converted using R statistical package (66) into a p value, i.e., the probability rate (where alpha = 1 -p is the statistical significance) as shown in Figure 1 For each SNP thus analyzed, the decision (Eq. 6) is the main result shown in the line "DECISION" of the "Result" textbox, and the p value can be found in the line "Z-score" (Figures 1, B and C).
It should be noted that before developing software Web-service SNP_TATA_Comparator (51) based on equations (1-6), the three-step molecular mechanism for the binding between TBP and the TATA box was predicted in silico (67) and detected in vitro 
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© 1996-2017 (68), and its bioinformatics model was repeatedly verified on independent experimental data (69-75) (for review, see (76)).
Hardware platform and software design
Web service SNP_TATA_Comparator (51) is a bioinformatics application installed on the hardware HP 380DL G6 under both virtualization "Citrix XenServer" and operating "CentOS 6" systems, which connect the Web server "Nginx + Apache," which is supported by the Siberian Supercomputer Center (Novosibirsk, Russia). It takes queried data from the reference human genome (5) using the BioPerl toolkit (52) as shown in Figure 1 B. Its bioinformatics model is the executable applet encoded primarily in the programming language C of the ANSI standard, which uses standard statistical software R (66). The user interface is written using standard Java-script. This Web service is publicly available (http://beehive. bionet.nsc.ru/cgi-bin/mgs/tatascan/start.pl). 
EXAMPLES OF KNOWN AND CANDIDATE SNP MARKERS (OF HEREDITARY DISEASES) THAT CAN ALTER TATA-BOXES OF HUMAN GENES

The human MBL2 gene
The human MBL2 gene (soluble mannosebinding lectin 2) contains one known SNP marker (rs72661131) of variable immunodeficiency (77), stroke (78), and preeclampsia (79). This SNP is a substitution of a minor c for an ancestral T at position -39 (hereafter denoted as -39T>c) in the promoter of this gene as shown in Figure 1 B. In the textbox "Result" in this figure, one can see that affinity estimates of the ancestral allele (20.17 "+/-" 0.12 ln units) are significantly stronger than the affinity corresponding to the minor allele (-39c; 19 .28 "+/-" 0.09 ln units; 4.19 nM) with the probability rate p > 0.999999 (Z = 11.97, alpha < 10-6 ). This SNP decreases affinity of TBP for the minor variant of the MBL2 promoter; this change corresponds to underexpression of this gene (designated as "Down" in Table 1 ), which is characterized by the negative value -0.87 of the SNPcaused change coefficient, kappa SNP (the natural logarithm of the ratio of the expression levels of ancestral and minor alleles of the SNP considered, i.e., kappa SNP = ln(K D,wt /K D,mt )). This prediction is consistent with clinical data on underexpression of this gene in patients with variable immunodeficiency (77), stroke (78), and preeclampsia (79).
Near this known biomedical SNP marker rs72661131, we found two unannotated SNPs (rs562962093 and rs567653539), which can cause MBL2 underexpression and overexpression, respectively ( Table 1 ). The first one can be associated with variable immunodeficiency, preeclampsia, and stroke as known for rs72661131. According to one more clinical study (80), both rs562962093 and rs567653539 can be candidate SNP markers of cardiovascular events in rheumatoid arthritis, which are significantly often associated with overexpression and underexpression of mannose-binding lectin 2 encoded by this gene (Table 1) .
Human HBB and HBD genes
Human HBB and HBD genes (beta-and delta-chains of hemoglobin, respectively) contain the largest number of SNP markers (rs34500389, rs33981098, rs33980857, rs34598529, rs33931746, rs397509430, and rs35518301) of resistance to malaria and thalassemia caused by underexpression of these genes (81). Near these biomedical SNP markers, there are three unannotated SNPs (rs63750953, rs281864525, and rs34166473) that can cause a hemoglobin deficiency. Thus, they can be considered candidate SNP markers of the same pathologies (Table 1) .
The human IL1B gene
The human IL1B gene (interleukin 1 beta) contains the most widely studied SNP marker (rs1143627) of gastric ulcer, chronic gastritis, gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, Graves' disease, obesity, and major depressive disorder (82-88), which were clinically shown to be associated with overexpression of this gene as shown in Table 1 . Near this known SNP marker, we found unannotated rs549858786, which was reported to lower IL1B expression (Table 1) , whereas an IL1B protein deficiency is a biochemical marker of rheumatoid arthritis (89), whose candidate SNP marker can thus be rs549858786 (51).
The human NOS2 gene
The human NOS2 gene (inducible nitric oxide synthase 2) contains an SNP marker of resistance to malaria as a beneficial effect (90) and epilepsy as an adverse effect (91). It is a -51T>C substitution (position 27800550 of the complementary DNA strand on chromosome 17 relative to the transcription start site of this gene (90)) that causes NOS2 overexpression according to clinical research (90, 91).
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© 1996-2017 Position (plus as the direct strand and minus as the complementary strand) on a chromosome within the framework of the current release GRCh38/hg38 of the reference human genome (5).
2 Ancestral (wt) and minor (mt)
alleles. Fisher's Z-score (the ratio of the difference between two means to the square root of the sum of the squares of their standard errors).
7
Significance: alpha = 1 -p, where p is probability ( Figure 1 , B and C).
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The human F3 gene
The human F3 gene encodes tissue thromboplastin (synonym: coagulation factor III). There is a known SNP marker (rs563763767) of an increased risk of venous thromboembolism and myocardial infarction in the promoter of this gene (92).
The human LEP gene
The human LEP gene encodes hormone leptin and has no known biomedical SNP markers that alter the promoter of this gene. Due to Friedman's discovery that the LEP gene is the "obesity gene" (93), three unannotated SNPs-rs34104384, rs200487063, and rs201381696-have been predicted as candidate SNP markers of obesity-caused hypertension (94, 95) and obesity (96) as shown in Table 1 according to their predicted effects on the affinity of TBP for the LEP promoter (97).
The human ABCA9 gene
The human ABCA9 gene (ATP-binding cassette subfamily A, member 9) is one more independent example of a human gene whose promoter has no known biomedical SNP markers near its known TATA box (98) ( Table 1) . Using Web service SNP_ TATA_Comparator (51), the candidate SNP marker rs367781716 of atherosclerosis, Alzheimer's disease (AD), and cardiovascular diseases was both predicted in silico and experimentally verified in vitro (99).
PRECLINICAL VERIFICATION IN VITRO AND EX VIVO OF THE CANDIDATE SNP MARKERS OF HEREDITARY DISEASES
These predictions of Web-service SNP_ TATA_Comparator (51) reviewed here were selectively verified under real-time (100-102), equilibrium (103), and nonequilibrium (97, 99, 104) conditions in vitro as well as under ex vivo conditions using cultured human cells transfected with the pGL 4.1.0 vector (Promega, USA) (reporter gene LUC (luciferase)) (105). In the text below, we discuss these experiments in more detail (for these in vitro verification experiments, fulllength human ТВР was expressed in Escherichia coli cells BL21 (DE3) and, then, purified by the standard protocol (106)).
Verification of candidate biomedical SNP markers using an electrophoretic mobility shift assay (EMSA) in vitro
The equilibrium dissociation constants (K D ) for the TBP-ODN complex (ODN: a given double-helical DNA 26-bp oligonucleotide synthesized and purified by BIOSYN (Novosibirsk, Russia), which is identical to either the minor or ancestral allele of a given SNP of the human gene promoter being tested, as shown in Table 1) (Table 1 ) and those measured under the nonequilibrium conditions in vitro (97, 104). As shown in this figure, the predictions of SNP_TATA_Comparator (51) are robust.
Verification of candidate biomedical SNP markers in real time in vitro using high-resolution spectrometer SX.20
The above-mentioned ODNs were synthesized, purified, and labeled at 5'-termini with fluorescent dyes TAMRA and FAM (BIOSYN, Novosibirsk, Russia). The working concentration of DNA duplexes in all cases was 10-7 М, concentration of the active ТВР at the initial stage was the same, and then was increased proportionally 2-, 4-, 6-, 8-, or 10-fold. Analysis of the time-series of magnitudes was conducted next (see Figure 5 in the illustrative case of the candidate SNP marker rs201381696), and construction of a kinetic model of the interaction of TBP with each DNA duplex and calculation of velocity constants of all elementary reactions were carried out by means of the Dynafit software (Biokin, USA). Table 1 ) by an electrophoretic mobility shift assay (EMSA) under equilibrium conditions in vitro. An example of electropherograms in the case of ancestral (panel A: norm, wild-type, wt) and minor (panel B: mutant, mt) alleles of the candidate SNP marker rs367781716 within the human ABCA9 gene promoter. (C) Experimental data: white and black squares depict the ancestral (norm, wild type, wt) and minor (mutant, mt) alleles, respectively, of the candidate SNP marker being verified as well as solid and dashed curves whose asymptotes estimate the values of the equilibrium dissociation constants (K D ) of the TBP-oligodeoxynucleotide (ODN) complexes as indicated below these curves. (D) The significant correlations between the in silico predicted kappa SNP values of the SNP-caused change coefficient (Table 1: natural logarithm of the ratio of quantitative estimates of the specific biological activity of ancestral (norm) and minor (mutant) alleles of the candidate SNP marker being verified) and those measured in vitro. Solid and dashed lines or curves denote the linear regression and boundaries of its 95% confidence interval, calculated by means of software package STATISTICA (Statsoft TM , USA); white and black circles depict the ancestral and minor alleles, respectively, of the candidate SNP markers being verified; r, R, tau, gamma, Chi-square, and alpha are Pearson's simple linear correlation, Spearman's rank correlation, Kendall's rank correlation, the Goodman-Kruskal generalized correlation, dichotic Chi-square correlation, and their significance, respectively; p is Fisher's exact test in the case of a 2 x 2 contingency table. 
Verification of candidate biomedical SNP markers using cultured human cell line under ex vivo conditions
Cell line HCT116 (human colon adenocarcinoma) was cultivated in a complete medium consisting of Dulbecco's modified Eagle's medium/ Nutrient mixture F-12 Ham, supplemented with 10% (v/v) of fetal bovine serum (Sigma), penicillin (100 U/ mL) and streptomycin (100 mg/mL) (BioloT). The culture was maintained at 37 O C in a humidified atmosphere containing 5% of CO 2 until the desired level of confluence. All the experiments were performed at 80-85% confluence. Oligonucleotides corresponding to ancestral and minor alleles of the predicted candidate SNP markers rs201381696, rs200487063, and rs34104384 (Table 1) were cloned into the pGL 4.10 vector (Promega, USA) and cotransfected with pRL-TK using Screen Fect A (InCella) as described elsewhere (107). After that, the cells were cultured in 6-well plates for 24 hours. Luciferase activity was measured by means of the Dual-Luciferase Reporter Assay kit (Promega). The results are presented in Figure 6 .
As readers can see in this figure, there is a significant linear correlation (panel B) between the predicted kappa SNP values of the SNP-caused change coefficient (Table 1 ) and those measured ex vivo (panel A). This finding can be an additional piece of supporting evidence for the robustness of the computer-based predictions of SNP_TATA_ Comparator (51). (Figures 3-6 ) together indicate that this Web-service (51) is accompanied by the comprehensive preclinical verification platform that allows for testing its predictions as soon as they are made.
Moreover, all the verification results
BIOMEDICAL PREDICTIONS USING A KEY WORDS SEARCH FOR KNOWN BIOMARKERS OF A HUMAN DISEASE IN DATABASES
The predictions in the cases of candidate SNP markers of obesity-related disorders (97), autoimmunerelated pathologies (108), chronopathologies (109), aggressiveness-related comorbidities (105), and sporadic AD (49) as well as resistance to antitumor chemotherapy (110) and social dominance/submission (111) were made using Web-service SNP_TATA_ Comparator (51). Below we selectively review these results in greater detail.
A Key Words search for known physiological markers of a human disease in the PubMed database
A Key Words search in the widely used PubMed database of biomedical publications (112) extends the predictive capabilities of Web service SNP_TATA_Comparator (51). (Table 1 : natural logarithm of the ratio of quantitative estimates of the specific biological activity of ancestral (norm) and minor (mutant) alleles of the candidate SNP marker being verified) was confirmed by those measured in vitro in real-time mode, namely: kappa SNP = ln(K D,wt /K D,mt ) = ln((4 nM)/(27 nM)) = ln(0.14) = -1.91 < 0.
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© 1996-2017 flow chart of a Key Words search for a comorbidity of hereditary diseases whose known and candidate SNP markers can alter a TBP-binding site in a human gene promoter. In this figure, two boxes (dashed lines) depict the primary Key Words search for these diseases whose known biochemical markers match the predicted significant changes of the gene expression caused by the SNP being analyzed. This primary result (Figure 7 : Result-1) can be seen in Table 1 as the predictions obtained by the Web service (51) regarding unannotated SNPs rs63750953, rs281864525, rs34166473, rs549858786, rs562962093, rs567653539, rs201381696, rs200487063, rs34104384, and rs367781716.
Additionally, Figure 7 shows a box outlined with a dotted line, which depicts a secondary manual Key Words search for co-occurrence of the comorbidities found in the first search and the hereditary disease clinically associated with the gene containing the SNP under study. According to the positive or negative outcome of this additional Key Words search, the SNP can be either predicted as a candidate SNP marker of a comorbidity of this hereditary disease (Figure 7 : Result-2) or discarded.
The clinical data found during the manual Key Words search (with the corresponding REFERENCES in two rightmost columns of the tables in this review) are indicated in italics and marked with the phrase "(likely)". Figure 7 . Below we discuss only some of these results in detail. The candidate SNP marker (rs72661131) of sporadic AD as a consequence of stroke (49) is quite interesting in our opinion. It is a genomewide marker suggesting that people who carry the minor allele of this SNP could minimize the risks of both diseases by adding some natural marine products into their diet (50). Of course, this is oversimplification: if stroke and sporadic AD could be prevented by a natural marine diet alone, the life of the general population would be very easy. Similarly, using the candidate SNP marker rs567653539, someone with a minor allele of this SNP can prevent cardiovascular disease, rheumatoid arthritis, and sporadic AD by switching to a diet enriched with selenium (Se) (119) . In addition, candidate SNP markers (rs33980857, rs34598529, rs33931746, rs63750953, rs281864525, rs35518301, and rs34166473) of sporadic AD as a comorbidity of thalassemia may mean that the functional food supplement fermented papaya can prevent these diseases (125) .
Examples of SNP markers of hereditary diseases as candidate SNP markers of sporadic Alzheimer's disease (AD)
Thus, these genomewide landmarks may be interesting for people who would like to bring their lifestyle in line with their sequenced individual genome. 
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© 1996-2017 6.3. Examples of SNP markers of hereditary diseases as candidate SNP markers of autoimmunity-related comorbidities Table 3 demonstrates the results of the Key Words search for autoimmunity-related comorbidities (108, . In our opinion, the candidate SNP marker (rs563763767) of Hughes syndromeassociated thrombosis (lethal during pregnancy (167, 168) ) is the most interesting because this syndrome is easy to diagnose early and is a preventable form of myocardial ischemia (169) . Using this genomewide landmark, a pregnant woman carrying the minor allele of this SNP and her physician can arrange additional diagnostics to detect the onset and development of this disease during her pregnancy to prevent its fatal outcome. Table 4 contains the results of the Key Words search for circadian rhythm-related comorbidities (170) (171) (172) (173) (174) (175) (176) (177) (178) (179) (180) (181) (182) , which are associated with consequences of desynchronoses either among the nervous, immune, digestive, respiratory, and other systems of the human body or between the human body and its environment (109) . The most interesting (in our opinion) known SNP marker of myocardial infarction and thrombosis (rs563763767) may indicate that these hereditary diseases have a circadian preference for the early morning (182) , which should correspond to the period of the strongest therapeutic effects of the medication used. In addition, candidate SNP markers rs33980857, rs34598529, rs33931746, rs63750953, rs281864525, rs35518301, and rs34166473 may indicate that during deferoxamine-based therapy in thalassemia, a patient can develop symptoms of sensorineural hearing loss as a complication of this drug (170, 171) . Therefore, additional analysis of hearing capacity in patients during this treatment may prevent this hearing loss (170, 171) . Table 5 shows the results of the abovementioned Key Words search on candidate SNP markers of obesity-related disorders (82, 94-97, 183-188). Looking through this table, one can see that obesity is a common comorbidity of all the hereditary diseases that have been selected for this review. The most generally accepted point of view is that obesity can lead to complications of many other diseases. Thus, our results suggest that prevention of obesity may further alleviate many other diseases, in line with the point of view above. Table 6 exemplifies the results of the Key Words search for aggressiveness-related complications (105, 189-210), which are associated with a hereditary behavioral trait that mobilizes all systems of the body-i.e., nervous, endocrine, respiratory, vascular, and muscular systems-for the defense of oneself, children, family, home, territory, possessions, business, ideas, or interests (211) . It is noteworthy that aggressiveness is a specific powerful internal stressor (whereby the human body mobilizes itself) that can negatively affect the lifespan (212). Here, it should be 1 Position (plus as the direct strand and minus as the complementary strand) on a chromosome within the framework of the current release GRCh38/ hg38 of the reference human genome (5).
Examples of SNP markers of hereditary diseases as candidate SNP markers of circadian rhythm-related comorbidities
Examples of SNP markers of hereditary diseases as candidate SNP markers of obesity-related comorbidities
Examples of SNP markers of hereditary diseases as candidate SNP markers of aggressiveness-related complications
emphasized that known SNP markers of hereditary diseases are the cause of the diseases in question. In contrast, candidate SNP markers of polygenic traits (e.g., aggressiveness) can only serve as genomewide informative markers of the increased or decreased risk relative to the norm among people who carry the minor alleles of these SNPs (108) . For example, using one whole-genome marker (rs201381696) of childhoodaggressiveness, parents of an aggressive 10-year-old girl with a minor allele of this candidate SNP marker may choose a diet and a physical exercise regimen for their daughter to prevent her obesity in adolescence and cardiovascular complications in adulthood (202). Similarly, using a candidate SNP marker (rs1143627) of aggressiveness as a complication of cytokine immunotherapy, a physician can prescribe an adjuvant © 1996-2017 antiaggression medication together with this main treatment procedure to a patient carrying a minor allele of this SNP (189, 196) . Candidate SNP markers (rs33980857, rs34598529, rs33931746, rs63750953, rs281864525, rs35518301, and rs34166473) of aggressiveness as a complication of hemodialysis in severe thalassemia can be used in a similar fashion (189, 196) . Furthermore, regarding the candidate SNP marker of higher aggressiveness in males subjected to environmental pollution with Pb (the -51T>C substitution, NOS2 gene promoter), people with a minor allele of this SNP can alter their lifestyle to minimize their contact with materials containing lead (197) . Therefore, this information could be interesting to people who would like to bring their lifestyle in line with their sequenced individual genome.
SUMMARY AND PERSPECTIVE
Currently, the widely used public database PubMed contains a huge number of clinical cases, retrospective reviews, research articles, laboratory data, and empirical findings from clinicians, nutritionists, pharmacists, physiologists, geneticists, psychologists, bioinformaticians, pedagogues, sociologists, legal scholars, economists, and other relevant experts such as specialists on insurance, management, health care, law enforcement, and 
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